Zacks Investment Research lowered shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a research report released on Wednesday morning.
According to Zacks, “LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “
Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus restated a buy rating on shares of LeMaitre Vascular in a research report on Sunday, October 29th. Canaccord Genuity decreased their target price on shares of LeMaitre Vascular from $30.00 to $29.00 and set a hold rating for the company in a research report on Friday, October 27th. Benchmark cut shares of LeMaitre Vascular from a buy rating to a hold rating in a research report on Friday, October 27th. First Analysis cut shares of LeMaitre Vascular from an overweight rating to an equal weight rating and set a $34.00 target price for the company. in a research report on Friday, October 27th. Finally, BidaskClub cut shares of LeMaitre Vascular from a hold rating to a sell rating in a research report on Saturday, December 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. LeMaitre Vascular has a consensus rating of Hold and an average target price of $32.20.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The business had revenue of $24.80 million during the quarter, compared to the consensus estimate of $25.49 million. During the same quarter in the prior year, the firm earned $0.17 EPS. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. analysts anticipate that LeMaitre Vascular will post 0.84 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, December 7th. Shareholders of record on Wednesday, November 22nd were given a $0.055 dividend. This represents a $0.22 annualized dividend and a yield of 0.72%. The ex-dividend date of this dividend was Tuesday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 28.21%.
In other LeMaitre Vascular news, insider David B. Roberts sold 4,123 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $32.14, for a total value of $132,513.22. Following the completion of the transaction, the insider now owns 24,482 shares in the company, valued at approximately $786,851.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 23.70% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. 361 Capital LLC bought a new position in shares of LeMaitre Vascular in the third quarter valued at approximately $1,973,000. Allianz Asset Management GmbH boosted its holdings in shares of LeMaitre Vascular by 4.7% in the third quarter. Allianz Asset Management GmbH now owns 321,820 shares of the medical instruments supplier’s stock valued at $12,042,000 after acquiring an additional 14,306 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of LeMaitre Vascular by 4.4% in the second quarter. Dimensional Fund Advisors LP now owns 968,232 shares of the medical instruments supplier’s stock valued at $30,228,000 after acquiring an additional 40,767 shares in the last quarter. State Street Corp boosted its holdings in shares of LeMaitre Vascular by 25.2% in the second quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock valued at $11,951,000 after acquiring an additional 77,009 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of LeMaitre Vascular by 137.5% in the third quarter. Rhumbline Advisers now owns 58,535 shares of the medical instruments supplier’s stock valued at $2,190,000 after acquiring an additional 33,891 shares in the last quarter. Institutional investors and hedge funds own 69.24% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “LeMaitre Vascular (LMAT) Downgraded to Hold at Zacks Investment Research” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2018/01/05/lemaitre-vascular-lmat-downgraded-to-hold-at-zacks-investment-research.html.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.